SynchroPet develops patented imaging technologies, including the RatCAP and Mini-PET, that enable whole brain imaging in awake rats and simultaneous PET/MRI scans. These tools provide researchers with quantitative PET images, enhancing the efficiency of drug discovery and improving clinical assessments without the need for invasive procedures.
Funding
Funding not disclosed
Founders
Product
Problem
Current PET and MRI imaging techniques often require invasive procedures or are limited by the size and mobility of traditional equipment. This can hinder drug discovery efforts and make clinical assessments less efficient.
Solution
SynchroPet develops and provides miniaturized PET imaging technologies, including the RatCAP and Mini-PET systems, designed to enhance preclinical and clinical research. The Mini-PET enables simultaneous PET/MRI scans, while the RatCAP allows for whole-brain imaging in awake, behaving rats. These compact and versatile tools provide quantitative PET images, potentially accelerating drug discovery, improving the reliability of therapy assessments, and opening new avenues for laboratory investigations. SynchroPet's technology offers an alternative to standard uptake value (SUV) measurements, facilitating quantitative disease and neurological assessments without the need for arterial catheters.
Target Audience
The primary target audience includes researchers in pharmaceutical development, clinical researchers, and those involved in infectious disease research.
Features
- Mini-PET system for simultaneous PET/MRI imaging
- RatCAP system for whole-brain imaging in awake rats
- Compact and portable designs for versatile use in various laboratory settings
- Quantitative PET imaging capabilities
- Potential to accelerate drug and radiopharmaceutical discovery
- Non-invasive alternative to arterial blood sampling for quantitative assessments